CCR 20th Anniversary Commentary: Divide and Conquer-Breast Cancer Subtypes and Response to Therapy.

Abstract

The article by Rouzier and colleagues, published in the August 15, 2005, issue of Clinical Cancer Research, demonstrated that different molecular subtypes of breast cancer have different degrees of sensitivity to chemotherapy, but the extent of response to neoadjuvant therapy has a different meaning by subtype. Several molecular subtype-specific clinical trials are under way to maximize pathologic complete response rates in triple-negative breast cancer and HER2-positive cancers, and to provide adjuvant treatment options for patients with residual invasive disease. See related article by Rouzier et al., Clin Cancer Res 2005;11(16) Aug 15, 2005;5678-85.

• Authors: Lajos Pusztai, Roman Rouzier, W Fraser Symmans
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 21 Issue 16 Pg. 3575-7 (Aug 15 2015) ISSN: 1557-3265 [Electronic] United States
• PMID: 26275950 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: ©2015 American Association for Cancer Research.

Chemical References

• ERBB2 protein, human
• Receptor, ErbB-2

Topics

• Anniversaries and Special Events
• Breast Neoplasms (classification, drug therapy, genetics)
• Female
• Humans
• Receptor, ErbB-2 (genetics)